Eric Carter
Direktor/Vorstandsmitglied bei AEON BIOPHARMA, INC.
Vermögen: - $ am 30.04.2024
Profil
Eric G.
Carter is currently a Non-Executive Director at AEON Biopharma Sub, Inc., a Director at Visgenx, Inc., and an Independent Director at AEON Biopharma, Inc. He previously worked as a Director at Bioniz Therapeutics, Inc., an Independent Director at Adverum Biotechnologies, Inc., the Chief Medical Officer & Senior Vice President at Allergan, Inc., the Chief Scientific & Medical Officer at KP Pharmaceuticals LLC, and the Vice President & Global Head at GSK Plc.
He also served as the Chief Medical Officer at Lundbeck Seattle BioPharmaceuticals, Inc. and as an Associate Professor at The University of North Carolina at Charlotte.
Additionally, he was the Chief Marketing Officer at IACTA Pharmaceuticals, Inc. Dr. Carter holds a doctorate degree from the University of Cambridge, a doctorate degree from the University of Miami, and an undergraduate degree from the University of London.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Eric Carter
| Unternehmen | Position | Beginn |
|---|---|---|
| AEON BIOPHARMA, INC. | Direktor/Vorstandsmitglied | 01.06.2023 |
AEON Biopharma Sub, Inc.
 AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | Direktor/Vorstandsmitglied | 24.07.2023 |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 01.01.2022 |
Ehemalige bekannte Positionen von Eric Carter
| Unternehmen | Position | Ende |
|---|---|---|
Bioniz Therapeutics, Inc.
 Bioniz Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA. | Direktor/Vorstandsmitglied | 01.02.2022 |
| ADVERUM BIOTECHNOLOGIES, INC. | Direktor/Vorstandsmitglied | 12.05.2021 |
| ALDER BIOPHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 17.01.2019 |
| ALLERGAN, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 |
KP Pharmaceuticals LLC
 KP Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology KP Pharmaceuticals LLC is a pharmaceuticals company which develops, manufactures, markets and sells branded prescription pharmaceutical products. The company was founded by John M. Gregory, Randal J. Kirk, Joseph R. Gregory, Jefferson J. Gregory and James E. Gregory in 1993 and is is headquartered in Bristol, TN. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 |
Ausbildung von Eric Carter
| University of Cambridge | Doctorate Degree |
| University of London | Undergraduate Degree |
| University of Miami | Doctorate Degree |
| The University of Miami Leonard M. Miller School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GSK PLC | Health Technology |
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| AEON BIOPHARMA, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
KP Pharmaceuticals LLC
KP Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology KP Pharmaceuticals LLC is a pharmaceuticals company which develops, manufactures, markets and sells branded prescription pharmaceutical products. The company was founded by John M. Gregory, Randal J. Kirk, Joseph R. Gregory, Jefferson J. Gregory and James E. Gregory in 1993 and is is headquartered in Bristol, TN. | Health Technology |
Bioniz Therapeutics, Inc.
Bioniz Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA. | Commercial Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | Health Technology |
IACTA Pharmaceuticals, Inc.
 IACTA Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology IACTA Pharmaceuticals, Inc. develops and commercializes eyecare products. Its products include IC 265, for dry eye, and IC 270, for allergic conjunctivitis. The company was founded by Damon Burrows, William Pedranti, and George K. Ng in 2016 and is headquartered in Irvine, CA. | Health Technology |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |
